NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis

Recursion Pharmaceuticals, Inc. (RXRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RXRX

$3.64

−$0.02 (−0.55%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RXRX with… →

RXRX Key Statistics

As of Oct 21, 2026
Trading
Open
$3.65
Previous Close
$3.66
Day's Range
3.56–3.76
52-Week Range
2.77–6.50
Volume
19.26M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.03
Valuation
Market Cap
$1.95B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
35.58
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.00
Financials (FY)
Revenue (FY)
$74.26M+26.96%
Net Income (FY)
−$644.76M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
535.34M
1-Year Return
−40.43%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
21.74M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RXRX closed at $3.64, −40.43% over 1 year.

Recursion Pharmaceuticals, Inc. (RXRX) has a market capitalization of $1.95B.

In fiscal 2025, RXRX reported revenue of $74.26M.

RXRX Stock Return by Calendar Year

Recursion Pharmaceuticals, Inc. (RXRX) return since Apr 2021: what $10,000 became

1 year
$10,000 $5,957
−40.43%
5 years
$10,000 $1,983
−80.17%
Since Apr 2021
$10,000 $1,163
−88.37%

If you had invested $10,000 in Recursion Pharmaceuticals, Inc. (RXRX) at the close on April 16, 2021, the earliest close on record here, it would have been worth $1,163 at the close on October 21, 2026: −88.37% in total, −32.31% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−11.00%
2025−39.50%
2024−31.44%
2023+27.89%
2022−54.99%
2021 (partial year)−45.27%

As of October 21, 2026.

RXRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$74.26M−$644.76M−868.3%
2024$58.49M−$463.66M−792.7%
2023$43.88M−$328.07M−747.7%
2022$39.68M−$239.48M−603.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$74.26M$3.30M−$648.13M−$644.76M−868.3%
2024$58.49M$13.25M−$479.00M−$463.66M−792.7%
2023$43.88M$1.29M−$350.06M−$328.07M−747.7%
2022$39.68M−$8.59M−$245.73M−$239.48M−603.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RXRX Valuation vs Biotechnology Median

Median of 608 stocks
MetricRXRXBiotechnology medianvs median
P/S ratio35.5813.30168% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Recursion Pharmaceuticals, Inc. (RXRX) is capitalised at $1.95B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 600 employees.

The most recent close on file for RXRX is $3.64, dated October 21, 2026. That is −$0.02 (−0.55%) against the previous close. Over the past 52 weeks the price has ranged from $2.77 to $6.50. The latest close sits 31.41% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $74.26M. That is +26.96% against the prior fiscal year, when revenue was $58.49M. The same year closed with a net loss of $644.76M. Trailing earnings per share are −1.

Across the 4 fiscal years on file, revenue moves from $39.68M in 2022 to $74.26M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 35.58. On price-to-sales that is 167.58% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.03. Annualized volatility over the trailing 5 years is 93.64%. Over the trailing twelve months the total return is −40.43%. Measured over 5 years, that is −27.65% a year compounded.

Growth & Income

No dividend is on file for RXRX.

So far in 2026 the total return is −11.00%. The strongest complete calendar year on file is 2023 at +27.89%; the weakest is 2022 at −54.99%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Recursion Pharmaceuticals, Inc. (RXRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Recursion Pharmaceuticals, Inc. RXRX $1.95B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Recursion Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Visit website →